Developer docs
API playgroundTry for free, no card

Search company profiles

Advanced Biological Laboratories (ABL)

Full company profile

uuid000b2ts

Namestring
Advanced Biological Laboratories (ABL)
Legal namestring
Advanced Biological Laboratories (ABL) S.A.
Websiteurl
ablsa.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Advanced Biological Laboratories (ABL) S.A. is a Luxembourg-headquartered European biotechnology and MedTech group founded in 2000 that develops and commercializes molecular diagnostics products for infectious disease and liver function assessment. The company operates primarily through its wholly-owned subsidiary ABL Diagnostics SA, which is listed on Euronext Paris (compartment C, ISIN FR001400AHX6), and through Humedics GmbH, a Berlin-based MedTech subsidiary acquired in December 2022 that owns the CE-marked LiMAx® breath-based liver function test.

ABL's product portfolio is built around two core molecular platforms: DeepChek® sequencing-based genotyping assays and software, and UltraGene® real-time PCR assays and instruments, together covering HIV, viral hepatitis B and C, CMV, HSV, HPV, SARS-CoV-2, tuberculosis, and 16S rRNA microbiome applications. The DeepChek® and ViroScore® software products perform downstream Sanger and NGS data analysis, genotyping, mutation detection, and clinical interpretation including drug resistance profiling, underpinned by a proprietary database described as the world's most complete collection of patented HBV drug resistance mutations. Beyond molecular diagnostics, ABL offers the Nadis® CE-marked Electronic Medical Record system deployed in more than 200 French hospitals for HIV and viral hepatitis patient management, the LiMAx® breath test for quantitative liver function measurement, and MediaChek® specimen collection kits.

ABL's business model combines one-time assay kit sales (UltraGene®, DeepChek® assays) with recurring revenue from software licenses and subscriptions (DeepChek® Software, ViroScore®) and SaaS-like EMR contracts (Nadis®). The company commercializes globally through its own sales team and a network of exclusive distributors across Africa, Asia Pacific, Europe, the Middle East, North America, and South America, with its technology active in more than 75 countries via the Humedics/CytoSorbents collaboration. ABL is founder-led by Dr. Chalom Sayada and is pursuing a proposed reverse merger with ProPhase Labs (NASDAQ:PRPH) that would give ABL shareholders approximately 76% of a combined Nasdaq-listed entity at up to $30 million enterprise value.

Short descriptiontext

Advanced Biological Laboratories (ABL) is a Luxembourg-based European biotech and MedTech group developing molecular diagnostics assays (DeepChek®, UltraGene®), bioinformatics software, and the LiMAx® breath-based liver function test, serving clinical pathology labs, reference labs, and hospitals across more than 75 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLuxembourg, Luxembourg
HQ citystring
Luxembourg
HQ countrystring
Luxembourg
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics software, clinical genomics analysis, PCR assay kits, infectious disease genotyping, liver function diagnostics
Industry4 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Laboratories621511
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Molecular Biology Products
TypeOne Time License
Description

Sale of innovative and proprietary molecular biology assays (UltraGene® and DeepChek® product lines) generating recurring revenues with primary focus on HIV, SARS-CoV-2, Tuberculosis, and viral hepatitis B and C applications.

ablsa.com
2Software Licenses and Subscriptions
TypeSubscription Recurring
Description

Commercialization of DeepChek® and ViroScore® software solutions for sequencing data analysis, with regular updates, quarterly upgrades, and cloud or local server deployment options.

ablsa.com
3Clinical Specimen Collection Kits
TypeOne Time License
Description

Manufacturing and marketing of MediaChek® kits for clinical specimen collection.

ablsa.com
4Digital Health Solutions
TypeSubscription Recurring
Description

Sale of Nadis®, a CE-marked Electronic Medical Record (EMR) system used in France in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.

ablsa.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1DeepChek
Description

Sequencing-based genotyping assays and downstream analysis software for microbiology and virology applications including HIV, HBV, HCV, CMV, HSV, HPV, Tuberculosis, Coronavirus, and microbiome analysis

ablsa.com
+6 more records
Core offering1 text field

Advanced Biological Laboratories (ABL) develops and commercializes molecular biology assays and downstream bioinformatics software for infectious disease diagnostics. Its DeepChek® and ViroScore® software platforms analyze Sanger and Next Generation Sequencing data for genotyping, subtyping, amino-acid mutation detection, and drug resistance interpretation across HIV, HBV, HCV, CMV, HSV, HPV, tuberculosis, SARS-CoV-2, and microbiome targets. UltraGene® real-time PCR assays provide CE-IVD marked viral load detection and variant screening, while the LiMAx® breath test (acquired via Humedics) measures enzymatic liver function and the Nadis® EMR system manages HIV and viral hepatitis patient records in over 200 French hospitals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Eliminates 51 manual connection steps in poxvirus downstream processing
+1 more record
Product overview1 text field

Advanced Biological Laboratories (ABL) offers a comprehensive molecular diagnostics portfolio centered on two core platforms: DeepChek® and ViroScore® software for downstream sequencing data analysis, and UltraGene® molecular assays for PCR-based detection and quantification. DeepChek® software handles Sanger and Next Generation Sequencing data for genomic analysis including genotyping, subtyping, and drug resistance interpretation across HIV, HCV, HBV, CMV, HSV, HPV, TB, and SARS-CoV-2. The companion UltraGene® assay line includes real-time PCR tests for viral load detection and variant screening, with products covering respiratory viruses (SARS-CoV-2, Influenza, RSV), viral hepatitis (HIV, HCV, HBV), and bacterial targets (TB, 16S rRNA). ABL also offers the LiMAx® breath analysis diagnostic (acquired via Humedics) for liver function measurement, the Nadis® EMR system for HIV/viral hepatitis patient management, and the MediaChek® specimen collection kits. The portfolio includes both CE-IVD marked diagnostic products and Research Use Only (RUO) assays, distributed globally through ABL Diagnostics SA (Euronext Paris listed) and a network of exclusive distributors.

Product and service24 records
1DeepChek® Software
CategorySoftware Platform
2ViroScore® Software
CategorySoftware Platform
3SeqHepB
CategorySoftware Platform
4BacterioChek®-TB Software
CategorySoftware Platform
5UltraGene® qPCR Instrument
CategoryInstrument
6MediaChek®
CategoryConsumable
7Nadis®
CategorySoftware Platform
8LiMAx®
CategoryDiagnostic Platform
9DeepChek® HIV Assay INT Genotyping and Drug Resistance
CategoryAssay Kit
10DeepChek® HIV Assay Protease / Reverse Transcriptase Genotyping and Drug Resistance
CategoryAssay Kit
11DeepChek® HCV 5'UTR Genotyping Assay
CategoryAssay Kit
12DeepChek® HCV NS3 Drug Resistance Assay
CategoryAssay Kit
13DeepChek® HCV NS5A Drug Resistance Assay
CategoryAssay Kit
14DeepChek® HCV NS5B Drug Resistance V4 Assay
CategoryAssay Kit
15DeepChek® HBV RT Genotyping and Drug Resistance Assay
CategoryAssay Kit
16DeepChek® CMV UL54/UL97 Assay
CategoryAssay Kit
17DeepChek® HSV TK/POL Assay
CategoryAssay Kit
18DeepChek® Whole Genome SARS-CoV-2 Genotyping Assay
CategoryAssay Kit
19DeepChek® 16S rRNA Bacterial Identification Assay
CategoryAssay Kit
20DeepChek® 13-Plex KB Drug Susceptibility Testing Assay
CategoryAssay Kit
21UltraGene® Assay SARS-CoV-2 VOC Screening and Determination
CategoryAssay Kit
22UltraQuant® Assay SARS-CoV-2 Quantification
CategoryAssay Kit
23UltraGene® Assay Combo 4 Screening
CategoryAssay Kit
24TherapyEdge®
CategorySoftware Platform
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Advanced BioScience Laboratories (ABL subsidiary) is part of Ginkgo Bioworks' multi-organization team for BARDA's BioMaP-Consortium contract (up to $22.2M) to develop domestic biomanufacturing of monoclonal antibodies targeting filoviruses. ABL contributes to scale production of 1C3 and 1C11 mAbs cocktail discovered by Emory University.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-22
Description

ABL signed licensing agreement with Institut Pasteur for HPV RNA-Seq Technology. HPV Transcriptome technology serves as a biomarker for detection, genotyping, and monitoring of HPV-associated cervical high-grade cytology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-02-03
Description

ABL signed know-how license and transfer agreement for Fast Track Diagnostics PCR portfolio from Siemens Healthineers. ABL and affiliates plan to start production and commercialization of new UltraGene products based on PCR tests previously supplied by Fast Track Diagnostics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-11
Description

Humedics GmbH (ABL subsidiary) and CytoSorbents announced theranostic collaboration in liver disease. Joint product promotion and comarketing program to increase market awareness, adoption, and sales of LiMAx® diagnostic and CytoSorb® therapy technologies across Europe (Germany, UK, France, Austria, Switzerland, Belgium, Netherlands, Luxembourg, Finland, Norway, Sweden, and Poland).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global molecular diagnostics and sample-preparation leader with PCR/qPCR and NGS-based assay menus (e.g., QIAstat-Dx) covering infectious diseases including HIV, HCV, HBV and TB — directly comparable to ABL's UltraGene®/DeepChek® clinical microbiology offerings, but at vastly greater scale.

TypeDirect peer
Description

South Korea-based molecular diagnostics specialist known for multiplex real-time PCR syndromic panels and proprietary assay design — closely mirrors ABL's UltraGene® quantitative PCR and Combo 4 respiratory panel strategy for infectious disease testing in clinical labs.

TypeBroad incumbent
Description

Diversified diagnostics company with FDA-cleared molecular assays (e.g., Panther system, Aptima HIV/HCV viral load assays) targeted at clinical laboratories — competes with ABL's CE-IVD HIV/HCV/HBV assay portfolio from a global installed-base advantage.

TypeBroad incumbent
Description

Developer of the GeneXpert molecular diagnostics platform with broad FDA-cleared infectious-disease menu (HIV, HCV, MTB, SARS-CoV-2) — competes head-to-head with ABL's assay offerings in reference and clinical labs and benefits from a much larger global installed base.

TypeBroad incumbent
Description

French in vitro diagnostics leader with strong microbiology and molecular infectious-disease franchises (BioBall, BIOFIRE, ARGENE) — directly comparable to ABL on TB/HIV/HCV molecular diagnostics and shares ABL Diagnostics' Euronext Paris corporate ecosystem.

TypeDirect peer
Description

European IVD company focused on molecular diagnostics (PCR-based) and clinical chemistry with similar mid-market positioning to ABL Diagnostics — overlapping customer base of academic and reference labs across EMEA.

TypeDirect peer
Description

Singapore-headquartered molecular diagnostics company with integrated PCR + NGS workflows for viral genotyping and resistance testing (HIV, HCV, HBV, influenza) and a similar reagent-plus-software value proposition to ABL's DeepChek®.

TypeBroad incumbent
Description

World's largest IVD player with cobas® and cobas® 6800/8800 molecular systems covering HIV, HCV, HBV, CMV viral-load testing and broader infectious-disease menu — sets the standard ABL's CE-IVD assays must compete against globally.

9Abbott Molecular
TypeBroad incumbent
Description

Division of Abbott with m2000 and Alinity m molecular platforms and FDA-cleared assays (HIV, HCV, HBV, CT/NG, SARS-CoV-2) — comparable assay menu across ABL's viral hepatitis/HIV/respiratory focus at much larger U.S. clinical scale.

TypeOthers
Description

Now an ABL subsidiary itself, Humedics originated the LiMAx® breath test — comparable as an enabling/adjacent business but illustrates the de-facto reference point for liver-function diagnostics competitors such as Echosens (FibroScan) and LiverMultiScan providers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Advanced Biological Laboratories (ABL)

Molecular Diagnostics Softwareablsa.com

Advanced Biological Laboratories (ABL) is a Luxembourg-based European biotech and MedTech group developing molecular diagnostics assays (DeepChek®, UltraGene®), bioinformatics software, and the LiMAx® breath-based liver function test, serving clinical pathology labs, reference labs, and hospitals across more than 75 countries.

What Advanced Biological Laboratories (ABL) does

Advanced Biological Laboratories (ABL) S.A. is a Luxembourg-headquartered European biotechnology and MedTech group founded in 2000 that develops and commercializes molecular diagnostics products for infectious disease and liver function assessment. The company operates primarily through its wholly-owned subsidiary ABL Diagnostics SA, which is listed on Euronext Paris (compartment C, ISIN FR001400AHX6), and through Humedics GmbH, a Berlin-based MedTech subsidiary acquired in December 2022 that owns the CE-marked LiMAx® breath-based liver function test.

ABL's product portfolio is built around two core molecular platforms: DeepChek® sequencing-based genotyping assays and software, and UltraGene® real-time PCR assays and instruments, together covering HIV, viral hepatitis B and C, CMV, HSV, HPV, SARS-CoV-2, tuberculosis, and 16S rRNA microbiome applications. The DeepChek® and ViroScore® software products perform downstream Sanger and NGS data analysis, genotyping, mutation detection, and clinical interpretation including drug resistance profiling, underpinned by a proprietary database described as the world's most complete collection of patented HBV drug resistance mutations. Beyond molecular diagnostics, ABL offers the Nadis® CE-marked Electronic Medical Record system deployed in more than 200 French hospitals for HIV and viral hepatitis patient management, the LiMAx® breath test for quantitative liver function measurement, and MediaChek® specimen collection kits.

ABL's business model combines one-time assay kit sales (UltraGene®, DeepChek® assays) with recurring revenue from software licenses and subscriptions (DeepChek® Software, ViroScore®) and SaaS-like EMR contracts (Nadis®). The company commercializes globally through its own sales team and a network of exclusive distributors across Africa, Asia Pacific, Europe, the Middle East, North America, and South America, with its technology active in more than 75 countries via the Humedics/CytoSorbents collaboration. ABL is founder-led by Dr. Chalom Sayada and is pursuing a proposed reverse merger with ProPhase Labs (NASDAQ:PRPH) that would give ABL shareholders approximately 76% of a combined Nasdaq-listed entity at up to $30 million enterprise value.

Advanced Biological Laboratories (ABL) firmographics

Firmographics
Name
Advanced Biological Laboratories (ABL)
Legal name
Advanced Biological Laboratories (ABL) S.A.
Website
https://ablsa.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Advanced Biological Laboratories (ABL) is a Luxembourg-based European biotech and MedTech group developing molecular diagnostics assays (DeepChek®, UltraGene®), bioinformatics software, and the LiMAx® breath-based liver function test, serving clinical pathology labs, reference labs, and hospitals across more than 75 countries.
Ownership category
akta.pro rank

Advanced Biological Laboratories (ABL) industry classification

Industry
Product category
Molecular Diagnostics Software
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Molecular diagnostics software
  • Clinical genomics analysis
  • PCR assay kits
  • Infectious disease genotyping
  • Liver function diagnostics

Where Advanced Biological Laboratories (ABL) is headquartered

Location

Headquarters

HQ city
Luxembourg
HQ country
Luxembourg
HQ region
Europe

Offices3 records

Markets served

Advanced Biological Laboratories (ABL) business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Molecular Biology Products: Sale of innovative and proprietary molecular biology assays (UltraGene® and DeepChek® product lines) generating recurring revenues with primary focus on HIV, SARS-CoV-2, Tuberculosis, and viral hepatitis B and C applications.
  2. Software Licenses and Subscriptions: Commercialization of DeepChek® and ViroScore® software solutions for sequencing data analysis, with regular updates, quarterly upgrades, and cloud or local server deployment options.
  3. Clinical Specimen Collection Kits: Manufacturing and marketing of MediaChek® kits for clinical specimen collection.
  4. Digital Health Solutions: Sale of Nadis®, a CE-marked Electronic Medical Record (EMR) system used in France in more than 200 hospitals managing patients infected by HIV or Viral Hepatitis.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Advanced Biological Laboratories (ABL) product offering

Product offering

Core offering

Advanced Biological Laboratories (ABL) develops and commercializes molecular biology assays and downstream bioinformatics software for infectious disease diagnostics. Its DeepChek® and ViroScore® software platforms analyze Sanger and Next Generation Sequencing data for genotyping, subtyping, amino-acid mutation detection, and drug resistance interpretation across HIV, HBV, HCV, CMV, HSV, HPV, tuberculosis, SARS-CoV-2, and microbiome targets. UltraGene® real-time PCR assays provide CE-IVD marked viral load detection and variant screening, while the LiMAx® breath test (acquired via Humedics) measures enzymatic liver function and the Nadis® EMR system manages HIV and viral hepatitis patient records in over 200 French hospitals.

Product overview

Advanced Biological Laboratories (ABL) offers a comprehensive molecular diagnostics portfolio centered on two core platforms: DeepChek® and ViroScore® software for downstream sequencing data analysis, and UltraGene® molecular assays for PCR-based detection and quantification. DeepChek® software handles Sanger and Next Generation Sequencing data for genomic analysis including genotyping, subtyping, and drug resistance interpretation across HIV, HCV, HBV, CMV, HSV, HPV, TB, and SARS-CoV-2. The companion UltraGene® assay line includes real-time PCR tests for viral load detection and variant screening, with products covering respiratory viruses (SARS-CoV-2, Influenza, RSV), viral hepatitis (HIV, HCV, HBV), and bacterial targets (TB, 16S rRNA). ABL also offers the LiMAx® breath analysis diagnostic (acquired via Humedics) for liver function measurement, the Nadis® EMR system for HIV/viral hepatitis patient management, and the MediaChek® specimen collection kits. The portfolio includes both CE-IVD marked diagnostic products and Research Use Only (RUO) assays, distributed globally through ABL Diagnostics SA (Euronext Paris listed) and a network of exclusive distributors.

Differentiator

Problem solved

Functional benefit

Brands

  • DeepChek: Sequencing-based genotyping assays and downstream analysis software for microbiology and virology applications including HIV, HBV, HCV, CMV, HSV, HPV, Tuberculosis, Coronavirus, and microbiome analysis
  • UltraGene
  • ViroScore
  • SeqHepB
  • Nadis
  • MediaChek
  • LiMAx

Products and services

  • DeepChek® Software
  • ViroScore® Software
  • SeqHepB
  • BacterioChek®-TB Software
  • UltraGene® qPCR Instrument
  • MediaChek®
  • Nadis®
  • LiMAx®
  • DeepChek® HIV Assay INT Genotyping and Drug Resistance
  • DeepChek® HIV Assay Protease / Reverse Transcriptase Genotyping and Drug Resistance
  • DeepChek® HCV 5'UTR Genotyping Assay
  • DeepChek® HCV NS3 Drug Resistance Assay
  • DeepChek® HCV NS5A Drug Resistance Assay
  • DeepChek® HCV NS5B Drug Resistance V4 Assay
  • DeepChek® HBV RT Genotyping and Drug Resistance Assay
  • DeepChek® CMV UL54/UL97 Assay
  • DeepChek® HSV TK/POL Assay
  • DeepChek® Whole Genome SARS-CoV-2 Genotyping Assay
  • DeepChek® 16S rRNA Bacterial Identification Assay
  • DeepChek® 13-Plex KB Drug Susceptibility Testing Assay
  • UltraGene® Assay SARS-CoV-2 VOC Screening and Determination
  • UltraQuant® Assay SARS-CoV-2 Quantification
  • UltraGene® Assay Combo 4 Screening
  • TherapyEdge®

Quantifiable outcome

  • Eliminates 51 manual connection steps in poxvirus downstream processing
  • +1 more outcomes

Companies that use Advanced Biological Laboratories (ABL)

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Advanced Biological Laboratories (ABL) technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

Feature6 records

Advanced Biological Laboratories (ABL) partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Ginkgo BioworkscoreStrategic or Co-development Partner · 4 November 2025Advanced BioScience Laboratories (ABL subsidiary) is part of Ginkgo Bioworks' multi-organization team for BARDA's BioMaP-Consortium contract (up to $22.2M) to develop domestic biomanufacturing of monoclonal antibodies targeting filoviruses. ABL contributes to scale production of 1C3 and 1C11 mAbs cocktail discovered by Emory University.
  • Institut PasteurcoreTechnology or Integration · 22 April 2025ABL signed licensing agreement with Institut Pasteur for HPV RNA-Seq Technology. HPV Transcriptome technology serves as a biomarker for detection, genotyping, and monitoring of HPV-associated cervical high-grade cytology.
  • Siemens HealthineerscoreTechnology or Integration · 3 February 2025ABL signed know-how license and transfer agreement for Fast Track Diagnostics PCR portfolio from Siemens Healthineers. ABL and affiliates plan to start production and commercialization of new UltraGene products based on PCR tests previously supplied by Fast Track Diagnostics.
  • CytoSorbents CorporationcoreStrategic or Co-development Partner · 11 July 2023Humedics GmbH (ABL subsidiary) and CytoSorbents announced theranostic collaboration in liver disease. Joint product promotion and comarketing program to increase market awareness, adoption, and sales of LiMAx® diagnostic and CytoSorb® therapy technologies across Europe (Germany, UK, France, Austria, Switzerland, Belgium, Netherlands, Luxembourg, Finland, Norway, Sweden, and Poland).

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Advanced Biological Laboratories (ABL) competitors and assessment

Company assessment

Broad incumbents

  • QIAGEN: Global molecular diagnostics and sample-preparation leader with PCR/qPCR and NGS-based assay menus (e.g., QIAstat-Dx) covering infectious diseases including HIV, HCV, HBV and TB — directly comparable to ABL's UltraGene®/DeepChek® clinical microbiology offerings, but at vastly greater scale.
  • Hologic: Diversified diagnostics company with FDA-cleared molecular assays (e.g., Panther system, Aptima HIV/HCV viral load assays) targeted at clinical laboratories — competes with ABL's CE-IVD HIV/HCV/HBV assay portfolio from a global installed-base advantage.
  • Cepheid (Danaher): Developer of the GeneXpert molecular diagnostics platform with broad FDA-cleared infectious-disease menu (HIV, HCV, MTB, SARS-CoV-2) — competes head-to-head with ABL's assay offerings in reference and clinical labs and benefits from a much larger global installed base.
  • bioMérieux: French in vitro diagnostics leader with strong microbiology and molecular infectious-disease franchises (BioBall, BIOFIRE, ARGENE) — directly comparable to ABL on TB/HIV/HCV molecular diagnostics and shares ABL Diagnostics' Euronext Paris corporate ecosystem.
  • Roche Diagnostics: World's largest IVD player with cobas® and cobas® 6800/8800 molecular systems covering HIV, HCV, HBV, CMV viral-load testing and broader infectious-disease menu — sets the standard ABL's CE-IVD assays must compete against globally.
  • Abbott Molecular: Division of Abbott with m2000 and Alinity m molecular platforms and FDA-cleared assays (HIV, HCV, HBV, CT/NG, SARS-CoV-2) — comparable assay menu across ABL's viral hepatitis/HIV/respiratory focus at much larger U.S. clinical scale.

Direct peers

  • Seegene: South Korea-based molecular diagnostics specialist known for multiplex real-time PCR syndromic panels and proprietary assay design — closely mirrors ABL's UltraGene® quantitative PCR and Combo 4 respiratory panel strategy for infectious disease testing in clinical labs.
  • ELITechGroup: European IVD company focused on molecular diagnostics (PCR-based) and clinical chemistry with similar mid-market positioning to ABL Diagnostics — overlapping customer base of academic and reference labs across EMEA.
  • Vela Diagnostics: Singapore-headquartered molecular diagnostics company with integrated PCR + NGS workflows for viral genotyping and resistance testing (HIV, HCV, HBV, influenza) and a similar reagent-plus-software value proposition to ABL's DeepChek®.

Others

  • Humedics: Now an ABL subsidiary itself, Humedics originated the LiMAx® breath test — comparable as an enabling/adjacent business but illustrates the de-facto reference point for liver-function diagnostics competitors such as Echosens (FibroScan) and LiverMultiScan providers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Advanced Biological Laboratories (ABL) social profiles

Digital presence

Advanced Biological Laboratories (ABL) compliance and trust

Trust signal

Compliance1 record

Advanced Biological Laboratories (ABL) financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Advanced Biological Laboratories (ABL) leadership team

Management profile

Number of profiles

Profiles2 records

Advanced Biological Laboratories (ABL) subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Advanced Biological Laboratories (ABL) funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Advanced Biological Laboratories (ABL) M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Biological Laboratories (ABL)

What does Advanced Biological Laboratories (ABL) do?

Advanced Biological Laboratories (ABL) develops and commercializes molecular biology assays and downstream bioinformatics software for infectious disease diagnostics. Its DeepChek® and ViroScore® software platforms analyze Sanger and Next Generation Sequencing data for genotyping, subtyping, amino-acid mutation detection, and drug resistance interpretation across HIV, HBV, HCV, CMV, HSV, HPV, tuberculosis, SARS-CoV-2, and microbiome targets. UltraGene® real-time PCR assays provide CE-IVD marked viral load detection and variant screening, while the LiMAx® breath test (acquired via Humedics) measures enzymatic liver function and the Nadis® EMR system manages HIV and viral hepatitis patient records in over 200 French hospitals.

Is Advanced Biological Laboratories (ABL) a public or private company?

Advanced Biological Laboratories (ABL) is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Advanced Biological Laboratories (ABL) founded?

Advanced Biological Laboratories (ABL) was founded in 2015. It employs 11 to 50 people.

Where is Advanced Biological Laboratories (ABL) based?

Advanced Biological Laboratories (ABL) is headquartered in Luxembourg, Luxembourg, in the Europe region.

How does Advanced Biological Laboratories (ABL) make money?

Four revenue lines are on record. Molecular Biology Products are the primary driver. The others are software Licenses and Subscriptions, clinical Specimen Collection Kits and digital Health Solutions.

Who are Advanced Biological Laboratories (ABL)'s main competitors?

Broad incumbents on record are QIAGEN, Hologic, Cepheid (Danaher), bioMérieux, Roche Diagnostics and Abbott Molecular. Direct peers are Seegene, ELITechGroup and Vela Diagnostics. Humedics is listed as an others.

Does Advanced Biological Laboratories (ABL) have an API?

No public API is recorded for Advanced Biological Laboratories (ABL).

What industry is Advanced Biological Laboratories (ABL) in?

Advanced Biological Laboratories (ABL)'s product category is Molecular Diagnostics Software. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarABL Diagnostics Informed that its Reference Shareholder ABL Has Crossed Below the 95% ThresholdABL Diagnostics announced that its reference shareholder ABL crossed below the 95% capital threshold, now holding 93.58% of capital and 95.90% of voting rights. This follows block trades since 2025 and is part of ABL's free float expansion strategy, which could reach up to 30% of share capital.EIN PresswireABL Diagnostics Announces Renewal of U.S. Patent (US 8,859,198 B2) for Hepatitis B Genotyping and Antiviral ResistanceABL Diagnostics renewed US patent 8,859,198 B2 for hepatitis B genotyping and antiviral resistance, originally granted in 2014. The patent covers detection of mutations affecting lamivudine, adefovir, entecavir, and tenofovir, with expiration around August 2029. The technology is licensed to reference laboratories, supporting recurring revenue.EIN PresswireAdvanced Biological Laboratories (ABL) S.A. Announces Entry of a New Private InvestorABL Luxembourg announced the entry of a new private investor through a minority shareholding acquisition, strengthening its shareholder base. Existing shareholders retain control, and governance arrangements remain unchanged. The group also noted preliminary discussions with a U.S. counterparty, though no definitive agreement was reached.GlobeNewswireProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological LaboratoriesProPhase Labs and Advanced Biological Laboratories signed a non-binding LOI for a reverse merger, with ABL expected to own about 76% of the combined entity. The deal may include a special cash dividend of up to $10 million and a carve-out of Crown Medical Collections receivables, with definitive agreements anticipated within 60-90 days.GlobeNewswireProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological LaboratoriesProPhase Labs, Inc. and Advanced Biological Laboratories S.A. have entered into a non-binding Letter of Intent for a proposed reverse merger, under which ABL would acquire approximately 76% ownership of the combined entity, with a preliminary valuation of legacy ProPhase assets at up to $30 million. As part of the transaction, current ProPhase shareholders may receive a special cash dividend of up to $10 million and benefit from carved-out Crown Medical Collections receivables expected to yield approximately $50 million net. The proposed transaction remains subject to due diligence, negotiation of definitive agreements, regulatory approvals, and other customary closing conditions, with the parties targeting execution of final documentation within 60 to 90 days.EIN PresswireAdvanced Biological Laboratories Signs Non-Binding LOI for Proposed Reverse Merger with ProPhase LabsAdvanced Biological Laboratories S.A. (ABL) and ProPhase Labs, Inc. (NASDAQ: PRPH) have signed a non-binding Letter of Intent for a proposed reverse merger, under which ABL shareholders would own approximately 76% of the combined company. The preliminary valuation of the legacy ProPhase business implies an enterprise value of up to $30 million, with current ProPhase shareholders potentially receiving a special cash dividend of up to $10 million and carved-out Crown Medical Collections receivables worth approximately $50 million. The transaction remains subject to due diligence, regulatory approvals, Nasdaq listing requirements, and execution of definitive agreements within approximately 60 to 90 days.PR NewswireAdvancedDx Biological Laboratories USA Commits to Bringing One Million COVID-19 Tests to the US Market Over the Next 90 DaysAdvancedDx Biological Laboratories USA (ABLDx) announced plans to bring one million COVID-19 molecular, serological, and genotypical tests to the US market over the next 90 days, with distribution targeted to communities including Boston and Miami. The company has received confirmation from the FDA on its Emergency Use Authorization application for the UltraGene Combo2Screen SARS-CoV-2 assay, which achieved 100 percent clinical reproducibility and targets two genes of the SARS-CoV-2 genome. ABLDx, a wholly-owned subsidiary of Luxembourg-based Advanced Biological Laboratories S.A., formed in 2019, stated the tests will include swab collection kits that have been in short supply within the USA.